olivLaw · US equity research
Waystar Holding Corp. WAY
Services-Computer Integrated Systems Design · SIC 7373 · Vertical: Services-Computer Integrated Systems Design (SIC 7373)
Waystar provides cloud-based, AI-powered software that helps healthcare providers collect payments accurately and faster across the full patient journey. Revenue grew 18% year-over-year in the second quarter of 2026, and the company raised its fiscal 2026 guidance, making its platform a relevant case in the US healthcare revenue cycle technology market. Fiscal 2025 revenue reached 1,099.3 million USD, and current guidance points to a range of 1.276 to 1.294 billion USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Waystar Holding Corp. (WAY) stock was 29.69 USD (+7.36% on the day), with market capitalisation 5.7 bn USD, P/E 42.9 on diluted EPS of 0.69 USD over the last 12 months, beta 0.73, 52-week range 17.31–37.04 USD. Latest reported quarter (Q3 2026): revenue of 325.6 m USD (+21.2% YoY), net income of 31.0 m USD (+1.2% YoY), diluted EPS 0.16 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 63.9
- strong (55–70)
- Bollinger (20, 2)
- 26.08 – 29.86
- in the upper half of the band · %B 0.95 · band width 13.5%
- SMA 50 / 200
- 26.34 / 23.91
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.72 / 0.76
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +12.1% | −2.0% | +14.1 pp | — |
| 3 months | +27.0% | −2.2% | +29.2 pp | — |
| 6 months | +49.2% | +4.3% | +44.9 pp | — |
| Year to date | −9.3% | +10.6% | −19.9 pp | — |
| 1 year | −20.8% | +10.5% | −31.3 pp | −34.8% |
| 3 years | unavailable | +73.7% | unavailable | −17.1% |
| 5 years | unavailable | +61.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244.1 m | 256.4 m | 270.7 m | 268.7 m | 303.5 m | 313.9 m | 319.7 m | 325.6 m |
| Cost of revenue | 79.5 m | 83.3 m | 87.0 m | 85.1 m | 92.6 m | 97.0 m | 97.7 m | 99.2 m |
| Research & development | 11.5 m | 11.1 m | 12.6 m | 12.4 m | 18.5 m | 18.4 m | 17.7 m | 20.3 m |
| Operating income | 53.1 m | 65.2 m | 64.8 m | 60.2 m | 59.0 m | 80.5 m | 76.0 m | 61.3 m |
| Depreciation & amortisation | 38.0 m | 33.4 m | 33.4 m | 33.3 m | 40.4 m | 41.5 m | 41.5 m | 41.5 m |
| Interest expense | — | 18.9 m | 18.3 m | 17.5 m | — | 20.6 m | 19.6 m | 19.3 m |
| Pre-tax income | 33.1 m | 46.3 m | 46.6 m | 42.7 m | 36.1 m | 59.8 m | 56.4 m | 42.0 m |
| Income tax | 14.0 m | 17.0 m | 14.4 m | 12.1 m | 16.2 m | 16.5 m | 15.5 m | 10.9 m |
| Net income | 19.1 m | 29.3 m | 32.2 m | 30.6 m | 20.0 m | 43.3 m | 40.9 m | 31.0 m |
| Diluted EPS | 0.11 ≈ | 0.16 | 0.18 | 0.17 | 0.10 ≈ | 0.22 | 0.21 | 0.16 |
| Operating cash flow | 64.8 m | 64.2 m | 96.8 m ≈ | 82.0 m ≈ | 66.6 m | 84.9 m | 59.4 m ≈ | 103.9 m ≈ |
| Capex | 6.2 m | 5.4 m | 5.8 m ≈ | 5.9 m ≈ | 9.4 m | 15.3 m | 16.1 m ≈ | 9.9 m ≈ |
| Share repurchases | 0 | — | — | 0 ≈ | 0 | — | — | 20.7 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 43 percentile of its own 7-quarter history (min 29.2, median 53.5, max 412.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 704.9 m | 791.0 m | 943.5 m | 1.1 bn |
| Revenue YoY | unavailable | +12.2% | +19.3% | +16.5% |
| Net income | -51.5 m | -51.3 m | -19.1 m | 112.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.42 | -0.42 | -0.13 | 0.61 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable |
| net % | -7.3% | -6.5% | -2.0% | 10.2% |
| Free cash flow | 85.2 m | 29.9 m | 142.5 m | 283.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 61.4 m USD
- Financial debt
- 1.5 bn USD
- Net debt
- 1.4 bn USD
- Equity
- 3.9 bn USD
- Total assets
- 5.8 bn USD
- Debt / equity
- 0.38x
- Current ratio
- 1.41x
- ROE
- 3.2%
- ROA
- 2.2%
- FCF margin
- 25.8%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Revenue | 704.9 m | 791.0 m | 943.5 m | 1.1 bn | SEC (XBRL)· 17 Feb 2026verified |
| Cost of revenue | 214.9 m | 249.8 m | 315.7 m | 348.2 m | SEC (XBRL)· 17 Feb 2026verified |
| Gross profit | 490.0 m ≈ | 541.2 m ≈ | 627.8 m ≈ | 751.1 m ≈ | SEC (XBRL)· 17 Feb 2026derived |
| Research & development | 32.8 m | 35.3 m | 48.8 m | 54.6 m | SEC (XBRL)· 17 Feb 2026verified |
| Operating income | 89.5 m | 142.1 m | 123.7 m | 249.3 m | SEC (XBRL)· 17 Feb 2026verified |
| Depreciation & amortisation | 183.2 m | 176.5 m | 186.6 m | 140.5 m | SEC (XBRL)· 17 Feb 2026verified |
| EBITDA | 272.6 m ≈ | 318.6 m ≈ | 310.4 m ≈ | 389.9 m ≈ | SEC (XBRL)· 17 Feb 2026derived |
| Pre-tax income | -65.9 m | -63.8 m | -22.5 m | 171.8 m | SEC (XBRL)· 17 Feb 2026verified |
| Income tax | -14.4 m | -12.5 m | -3.4 m | 59.7 m | SEC (XBRL)· 17 Feb 2026verified |
| Net income | -51.5 m | -51.3 m | -19.1 m | 112.1 m | SEC (XBRL)· 17 Feb 2026verified |
| Diluted EPS | -0.42 | -0.42 | -0.13 | 0.61 | SEC (XBRL)· 17 Feb 2026verified |
| Weighted average diluted shares | 121.7 m | 121.7 m | 149.9 m | 184.8 m | SEC (XBRL)· 17 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 64.6 m | 35.6 m | 182.1 m | 61.4 m | SEC (XBRL)· 17 Feb 2026verified |
| Receivables | — | 126.1 m | 145.2 m | 177.0 m | SEC (XBRL)· 17 Feb 2026verified |
| Current assets | — | 222.1 m | 371.0 m | 308.4 m | SEC (XBRL)· 17 Feb 2026verified |
| Goodwill | 3.0 bn | 3.0 bn | 3.0 bn | 4.0 bn | SEC (XBRL)· 17 Feb 2026verified |
| Intangibles (excl. goodwill) | — | 1.2 bn | 1.0 bn | 1.3 bn | SEC (XBRL)· 17 Feb 2026verified |
| Total assets | — | 4.6 bn | 4.6 bn | 5.8 bn | SEC (XBRL)· 17 Feb 2026verified |
| Accounts payable | — | 45.5 m | 47.4 m | 50.9 m | SEC (XBRL)· 17 Feb 2026verified |
| Short-term debt | — | 18.0 m | 11.7 m | 14.2 m | SEC (XBRL)· 17 Feb 2026verified |
| Long-term debt | — | 2.2 bn | 1.2 bn | 1.5 bn | SEC (XBRL)· 17 Feb 2026verified |
| Current liabilities | — | 123.5 m | 145.6 m | 218.1 m | SEC (XBRL)· 17 Feb 2026verified |
| Total liabilities | — | 2.5 bn | 1.5 bn | 1.9 bn | SEC (XBRL)· 17 Feb 2026verified |
| Equity | 2.1 bn † | 2.0 bn † | 3.1 bn † | 3.9 bn † | SEC (XBRL)· 17 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | 102.6 m | 51.5 m | 169.8 m | 309.7 m | SEC (XBRL)· 17 Feb 2026verified |
| Capex | 17.4 m | 21.5 m | 27.3 m | 26.5 m | SEC (XBRL)· 17 Feb 2026verified |
| Free cash flow | 85.2 m ≈ | 29.9 m ≈ | 142.5 m ≈ | 283.2 m ≈ | SEC (XBRL)· 17 Feb 2026derived |
| Investing cash flow | -17.4 m | -61.5 m | -27.3 m | -680.9 m | SEC (XBRL)· 17 Feb 2026verified |
| Financing cash flow | -67.1 m | -17.2 m | 16.7 m | 243.5 m | SEC (XBRL)· 17 Feb 2026verified |
| Share repurchases | 2.5 m | 688.0 k | 844.0 k | 0 | SEC (XBRL)· 17 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
4 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 64 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 5.7 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation51
- Returns43
- Quality82
- Balance sheet58
- Growth66
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.00 – 26.31 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/Sales0.00 – 5.85 (Mid 0.23)11 companies used · median multiple 1.2x · quartiles 0.8x – 2.0xCACI, CREX, DAIC, FUSE, GDDY, HCTI, KD, LDOS, OTEX, RBBN, SAIC
- Peers: EV/EBITDA19.70 – 26.31 (Mid 22.18)4 companies used · median multiple 12.9x · quartiles 11.8x – 14.7xASUR, CACI, GDDY, SAIC
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 64/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| Gross margin · Quality | 69.4% | 73 (on a fixed band) | 11% |
| EBIT margin · Quality | 21.9% | 91 (vs peers) | 9% |
| FCF margin · Quality | 20.9% | 84 (on a fixed band) | 9% |
| Revenue CAGR 3Y · Growth | 16.0% | 64 (on a fixed band) | 17% |
| Revenue growth (YoY) · Growth | 16.5% | 70 (vs peers) | 9% |
| Net debt / EBITDA · Balance sheet | 3.2x | 40 (vs peers) | 6% |
| Current ratio · Balance sheet | 2.1x | 77 (on a fixed band) | 6% |
| EV/Sales · Valuation | 5.7x | 20 (vs peers) | 17% |
| FCF yield · Valuation | 4.6% | 92 (on a fixed band) | 13% |
| Shareholder yield (distributions) · Returns | 0.6% | 43 (on a fixed band) | 4% |
Score groups
- Balance sheet58/100 · 2/2 factors with a value
- Growth66/100 · 2/2 factors with a value
- Quality82/100 · 3/3 factors with a value
- Returns43/100 · 1/1 factors with a value
- Valuation51/100 · 2/2 factors with a value
Memo
Waystar Holding Corp. (WAY). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 1.1 bn USD in 2025; YoY growth 16.5%; net margin 10.7%; ROE 3.7%; net debt/EBITDA 3.2x.
The estimated value range is 9.85–16.08 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 11.20 USD, the price of 29.69 USD leaves a potential of -62.3% (value / price − 1) and a margin of safety of -165.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 64/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Gross margin: 69.4%
- EBIT margin: 21.9%
- FCF margin: 20.9%
- Revenue growth (YoY): 16.5%
- Current ratio: 2.1x
- FCF yield: 4.6%
What contradicts it
- EV/Sales: 5.7x
- The price is above the estimated value range
- The valuation methods diverge
Versus the vertical median
Services-Computer Integrated Systems Design (SIC 7373) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LDOSLeidos Holdings, Inc. | 16.4 bn | 12.1 | 28.2% | 8.0% | +3.1% | −30% / +26% |
| GDDYGoDaddy Inc. | 14.3 bn | 16.2 | — | 18.6% | +8.3% | −7% / +18% |
| CACICACI International Inc | 14.0 bn | 25.9 | 12.5% | 5.5% | +10.9% | +2% / +97% |
| JKHYJack Henry & Associates, Inc. | 12.6 bn | 25.7 | 24.0% | 19.8% | +7.1% | +3% / +13% |
| IONQIonQ, Inc. | 11.3 bn | — | -60.8% | -553.3% | +201.9% | −40% / +142% |
| OTEXOpen Text Corp | 6.4 bn | 10.3 | 16.2% | 12.3% | +1.5% | −21% / −34% |
| SAICScience Applications International Corporation | 6.3 bn | 17.6 | 25.7% | 5.1% | −2.9% | +75% / +28% |
| WAYWaystar Holding Corp. | 5.7 bn | 42.9 | 3.7% | 10.7% | +16.5% | −21% / unavailable |
| KDKyndryl Holdings, Inc. | 3.7 bn | 46.2 | 7.6% | 0.6% | +0.2% | −35% / −7% |
| AGYSAgilysys, Inc. | 3.5 bn | 78.5 | 13.6% | 12.9% | +15.9% | −0% / +42% |
| NTCTNetscout Systems Inc | 2.8 bn | 23.3 | 7.5% | 13.7% | +4.5% | +42% / +90% |
| AURAurora Innovation, Inc. | 2.6 bn | — | -45.7% | -13,328.6% | unavailable | −3% / +86% |
| PONYPony AI Inc. | 2.1 bn | — | -10.3% | -148.9% | +20.0% | −65% / unavailable |
| OSPNOneSpan Inc. | 872.9 m | 13.2 | 26.8% | 27.5% | +0.0% | +94% / +136% |
| TLSTelos Corporation | 378.2 m | — | -14.9% | -8.1% | +52.2% | −12% / +23% |
| SLPSimulations Plus, Inc. | 374.2 m | 46.7 | 6.2% | 9.9% | +13.1% | unavailable / unavailable |
| SMRTSmartrent, Inc. | 310.4 m | — | -8.4% | -13.0% | −12.9% | −6% / −48% |
| ASURAsure Software, Inc. | 293.6 m | — | -1.9% | — | +24.3% | +22% / +22% |
| VEEAVeea Inc. | 281.2 m | — | — | -2,491.9% | +56.6% | −55% / −98% |
| RBBNRibbon Communications Inc. | 275.9 m | 22.5 | 5.0% | 2.3% | +1.3% | −46% / −28% |
| KDKKodiak AI, Inc. | 220.7 m | — | — | -4,259.6% | −74.6% | −82% / unavailable |
| AIOSAIOS Tech Inc. | 138.9 m | — | -208.9% | -4,359.1% | −98.5% | −87% / −86% |
| MRLNMerlin, Inc. | 91.5 m | — | — | — | unavailable | −92% / unavailable |
| CSPICSP Inc | 75.4 m | — | -1.5% | -1.2% | +6.4% | −35% / −40% |
| HCTIHealthcare Triangle, Inc. | 69.2 m | — | -57.4% | -66.3% | +18.8% | −97% / −100% |
1- and 3-year price returns: for WAY from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 19.69 Total return -34% · Per year -34% | 34.65 Total return 17% · Per year 17% | 51.98 Total return 75% · Per year 75% |
| 3 years | 23.36 Total return -21% · Per year -8% | 45.83 Total return 54% · Per year 16% | 74.85 Total return 152% · Per year 36% |
| 5 years | 27.70 Total return -7% · Per year -1% | 60.61 Total return 104% · Per year 15% | 107.78 Total return 263% · Per year 29% |
- Exit P/E± 11.46
- Net margin± 8.02
- Annual revenue growth± 5.98
- Annual dilution± 0.67
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (02 Nov 2026 · results), 10-Q (02 Nov 2026).
In brief
Waystar provides cloud-based, AI-powered software that helps healthcare providers collect payments accurately and faster across the full patient journey. Revenue grew 18% year-over-year in the second quarter of 2026, and the company raised its fiscal 2026 guidance, making its platform a relevant case in the US healthcare revenue cycle technology market. Fiscal 2025 revenue reached 1,099.3 million USD 1, and current guidance points to a range of 1.276 to 1.294 billion USD 3.
SWOT
Strengths
- A unified cloud platform, an extensive transaction database and a high client retention rate 1.
- Deep integrations with many healthcare systems make replacing the vendor harder for clients 1.
- Largely recurring revenue and a diversified client base, where the ten largest clients represent a small share of the total 1.
Weaknesses
- Larger competitors have greater financial resources and brand recognition, which could limit the company's growth 1.
- Dependence on integrations with EHR and PM vendors means changes on their side can affect operations 1.
- Recent acquisitions such as Iodine bring integration risks and can affect comparability of results from one quarter to another 1.
Opportunities
Risks
- Intense competitionhigh
Larger or better-funded competitors could gain market share, and the entry of large technology companies could accelerate this trend 1.
- Client retentionhigh
If clients decline to renew or renegotiate at lower rates, revenue growth could slow 1.
- Acquisition integrationmedium
Difficulties integrating acquired businesses could affect announced synergies and financial results 1.
- Partner dependencemedium
Changes in terms from EHR and PM vendors or channel partners could affect product distribution 1.
- Healthcare transaction volumeslow
Revenue depends on the growth of clients and on healthcare transaction volumes, factors outside the company's control 1.
Investment thesis
What would need to be true (bull case)
- Revenue growth and the raised 2026 guidance suggest that demand for the platform remains solid 3.
- High net revenue retention and a large client base suggest the products are hard to replace 13.
- The estimated addressable market and the still-small market share leave room for growth in coming years, if the AI strategy holds up 1.
What would break the thesis
- Competition from large technology companies and EHR vendors could limit growth and margins 1.
- Integrating the Iodine acquisition and keeping results comparable could remain difficult in the coming period 1.
- If provider budgets tighten, new contracts could slow and renewals could come on less favorable terms 1.
What to watch
- Trend in the net revenue retention rateQ3 2026
- Integration and contribution of the Iodine acquisition2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 29 Jul 2026; since then the company filed 8-K (02 Nov 2026 · results), 10-Q (02 Nov 2026).
The business
Waystar Holding Corp. (Nasdaq: WAY) provides healthcare organizations with mission-critical AI-powered software that simplifies healthcare payments for providers, from physician practices to large hospital systems 1. The platform covers the full payment workflow, from eligibility checks and prior authorization to denied-claim appeals and patient payment collection 1. The company says its services help reduce billing errors and speed up collections, and its clients use the platform daily 1.
Market context
The company estimates that its US addressable market was 20 billion USD in 2025 and could reach almost 25 billion USD by 2030, based on a 5% compound annual growth rate 1. Administrative costs in healthcare are considerable, and digitization of the revenue cycle could support demand for such solutions 1.
Trends
- AI adoption in the revenue cycletailwind
Growing use of artificial intelligence to automate claims and documentation could strengthen the company's position if providers keep replacing manual processes with software 1.
- Administrative cost pressuremixed
Labor costs in hospitals and billing errors create demand for automation, but tight provider budgets could slow new purchases 1.
- Consolidation in healthcaremixed
Mergers among providers and health systems can extend existing contracts, but they can also reduce the number of independent clients or change renewal terms 1.
- Shift from legacy to cloud systemstailwind
Providers moving from on-premises systems to cloud platforms could bring new clients, provided integrations remain simple and fast 1.
Competitive position
The company's differentiation rests on its unified cloud platform, its payer network and the data accumulated from transactions, which would be hard for new entrants to replicate 1. However, the entry of large technology companies into the revenue cycle market could shift the competitive balance 1.
- EHR and PM system vendors
Companies that already integrate Waystar solutions but could also offer competing claims and payment management features 1.
- Niche revenue cycle firms
Smaller companies specializing in particular stages of the payment process that can compete on lower costs 1.
- Large technology companies
Well-funded firms increasingly entering the healthcare revenue cycle technology market 1.
- Outsourcing service providers
Administrative process providers that can offer software-combined services, competing with automated solutions 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Waystar Surges As Medical Software Maker Reportedly Mulls A SaleYahoo Finance — News · 15 Sept 2026 · EN
- Exclusive-Healthcare software firm Waystar explores options including sale, sources sayCNA (Channel NewsAsia) · 15 Sept 2026 · EN
The latest news item in our archive is from 15 Sept 2026; the newest SEC filing is from 02 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report02 Nov 2026
- Current report02 Nov 2026Results of operations · Financial statements and exhibits
- Quarterly report29 Jul 2026
- Current report29 Jul 2026Results of operations · Financial statements and exhibits
- Current report04 Jun 2026Shareholder vote
- Quarterly report29 Apr 2026
- Current report29 Apr 2026Results of operations · Financial statements and exhibits
- Proxy statement17 Apr 2026
- Annual report17 Feb 2026
- Current report17 Feb 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Waystar Holding Corp. · 17 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Waystar Holding Corp. · 29 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Waystar Holding Corp. · 29 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.